Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:GELS NASDAQ:KTTA NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.08+9.4%$0.98$0.55▼$1.19$12.64M0.83165,997 shs567,731 shsGELSGelteq$0.87-16.3%$0.64$0.39▼$2.02$11.14M-0.1911.20 million shs343,097 shsKTTAPasithea Therapeutics$0.54+7.8%$0.69$0.28▼$2.06$12.47M0.25455,618 shs546,112 shsSNYRSynergy CHC$0.22-6.3%$0.32$0.19▼$4.00$3.60M-0.276.79 million shs456,538 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%+14.09%+22.26%+16.35%+61.27%GELSGelteq0.00%+5.05%+146.45%+46.44%-35.00%KTTAPasithea Therapeutics0.00%-14.90%-28.12%-34.68%-32.75%SNYRSynergy CHC0.00%+21.94%-6.27%-79.57%-90.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.08+9.4%$0.98$0.55▼$1.19$12.64M0.83165,997 shs567,731 shsGELSGelteq$0.87-16.3%$0.64$0.39▼$2.02$11.14M-0.1911.20 million shs343,097 shsKTTAPasithea Therapeutics$0.54+7.8%$0.69$0.28▼$2.06$12.47M0.25455,618 shs546,112 shsSNYRSynergy CHC$0.22-6.3%$0.32$0.19▼$4.00$3.60M-0.276.79 million shs456,538 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera0.00%+14.09%+22.26%+16.35%+61.27%GELSGelteq0.00%+5.05%+146.45%+46.44%-35.00%KTTAPasithea Therapeutics0.00%-14.90%-28.12%-34.68%-32.75%SNYRSynergy CHC0.00%+21.94%-6.27%-79.57%-90.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 2.00HoldN/AN/AGELSGelteq 1.00SellN/AN/AKTTAPasithea Therapeutics 2.00Hold$3.00456.69% UpsideSNYRSynergy CHC 2.00Hold$6.252,690.18% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, KTTA, BFRI, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/12/2026SNYRSynergy CHC Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/11/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$41.71M0.33N/AN/A$0.90 per share1.20GELSGelteq$110K84.77N/AN/A$1.08 per share0.81KTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/ASNYRSynergy CHC$30.38M0.11N/AN/A($2.06) per share-0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$10.54M-$0.97N/A18.00N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)GELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)SNYRSynergy CHC-$12.34M-$1.40N/A1.49N/A-60.02%-19.51%-30.30%N/ALatest SNYR, KTTA, BFRI, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 million5/14/2026Q1 2026SNYRSynergy CHC$0.03-$0.23-$0.26-$0.23N/A$5.49 million3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera0.781.201.09GELSGelteqN/AN/AN/AKTTAPasithea TherapeuticsN/A35.4135.41SNYRSynergy CHCN/A0.930.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%GELSGelteqN/AKTTAPasithea Therapeutics23.92%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera8.10%GELSGelteqN/AKTTAPasithea Therapeutics2.00%SNYRSynergy CHC32.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7012.80 million11.77 millionNo DataGELSGelteqN/A10.71 millionN/AN/AKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableSNYRSynergy CHC4015.08 million10.12 millionN/ASNYR, KTTA, BFRI, and GELS HeadlinesRecent News About These CompaniesAscendiant Capital Markets Forecasts Synergy CHC Q2 EarningsJune 15, 2026 | americanbankingnews.comSynergy CHC Corp. Stock Short Interest Rises to 42.12%June 10, 2026 | quiverquant.comQSynergy CHC (SNYR)May 30, 2026 | invezz.comISynergy CHC Corp SNYRMay 19, 2026 | morningstar.comMSynergy CHC Receives Nasdaq Minimum Bid Price NoticeMay 18, 2026 | tipranks.comSynergy Hesitates on Quarterly NumbersMay 15, 2026 | baystreet.caSynergy CHC Corp. (SNYR) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2026 | zacks.comSynergy CHC Corp. Reports First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comSynergy CHC Establishes Equity Line Financing AgreementMay 11, 2026 | tipranks.comSynergy CHC Corp. Stock Short Interest Rises to 35.83%May 5, 2026 | quiverquant.comQSynergy CHC Corp. (NASDAQ:SNYR) Short Interest Up 3,525.7% in AprilApril 25, 2026 | defenseworld.netDSynergy CHC shares surge nearly 100% in after-hours trading: What's going on?April 14, 2026 | msn.comSynergy CHC Corp. (NASDAQ:SNYR) Q4 2025 Earnings Call TranscriptApril 3, 2026 | insidermonkey.comSynergy CHC Corp (SNYR) Q4 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...April 1, 2026 | finance.yahoo.comSynergy CHC Corp. (SNYR) Q4 2025 Earnings Call TranscriptApril 1, 2026 | seekingalpha.comSynergy CHC delays annual Form 10-K filingApril 1, 2026 | tipranks.comSynergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial ResultsApril 1, 2026 | globenewswire.comSynergy CHC Corp. Announces New Release Date for Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 | quiverquant.comQSynergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference CallMarch 30, 2026 | globenewswire.comSynergy CHC (NASDAQ:SNYR) versus Colgate-Palmolive (NYSE:CL) Critical ReviewMarch 29, 2026 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, KTTA, BFRI, and GELS Company DescriptionsBiofrontera NASDAQ:BFRI$1.08 +0.09 (+9.42%) Closing price 04:00 PM EasternExtended Trading$1.09 +0.01 (+0.93%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Gelteq NASDAQ:GELS$0.87 -0.17 (-16.28%) Closing price 04:00 PM EasternExtended Trading$0.87 +0.00 (+0.15%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Pasithea Therapeutics NASDAQ:KTTA$0.54 +0.04 (+7.78%) Closing price 04:00 PM EasternExtended Trading$0.54 0.00 (-0.35%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Synergy CHC NASDAQ:SNYR$0.22 -0.02 (-6.28%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
